Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 28, 2019

View Archived Issues

Microbiome ineffective at remyelination support

A whole parasite vaccination approach against malaria presented

IBI-315 begins phase I trial in China for HER2-expressing advanced solid malignancies

Anti-CD39 antibody ES-002 demonstrates efficacy in multiple myeloma xenograft model

ZW-25 shows promising single-agent antitumor activity in advanced HER2-expressing cancers

Global phase III study of trastuzumab biosimilar HLX-02 meets primary endpoint

Patient recruitment ongoing in phase I/II study of BTZ-043 in pulmonary tuberculosis

Subcutaneous infliximab biosimilar approved in the E.U. for the treatment of RA

TMAO is associated with diffuse cardiac fibrosis in HIV-positive individuals

Merck KGaA presents phase I data for the novel antimalarial candidate M-5717

Peroxiredoxin-1 as a novel therapeutic target in LPS-induced AKI

Identification of exosomal miRNAs as novel biomarkers and therapeutic targets in ADPKD

AstraZeneca identifies new TRPC3 and TRPC6 antagonists

Imago Biosciences describes new KDM1A inhibitors

G12C-mutant GTPase KRAS inhibitors patented by Amgen

Myungmoon Bio, Kyungpook National University disclose new anticancer compounds

LG Chem discovers new enteropeptidase inhibitors

"Absolutely fascinating": Stem cells, dead cells work equally well for heart repair

iRNA therapy ARO-APOC3 reduces triglycerides in healthy volunteers

Lonza and DiNAQOR collaborate to advance gene therapy programs for monogenic cardiomyopathies

Prokarium receives MHRA clearance to begin first-in-human study of enteric fever vaccine Entervax

Lilly initiates phase II study of LY-3454738 in chronic spontaneous urticaria

Henlius reports phase I data on anti-PD-1 antibody HLX-10 in advanced solid tumors

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 8, 2026.
New York University identifies new analogues of mannose-6-phosphate
BioWorld Science
New York University has discovered new analogues of mannose-6-phosphate reported to be potentially useful for the treatment of memory impairment,...
ASCO 2026: Chinese biopharma arrives at ASCO with pivotal wins
BioWorld
If the 2026 American Society of Clinical Oncology (ASCO) annual meeting in Chicago from May 30 to June 3 demonstrated anything about the evolution of China’s...
Bial-Portela discovers new OX1 receptor antagonists
BioWorld Science
Bial-Portela & Ca SA has patented new orexin OX1 receptor antagonists potentially useful for the treatment of anxiety disorders, depression, eating disorders,...
Autobahn on the fast track with bipolar thyroid agonist
BioWorld
Achieving high marks in the phase II Amplify-BD trial for bipolar I and II depression, Autobahn Therapeutics Inc.’s elunetirom, a brain-penetrant central nervous...